Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin Phase II Dose-Finding Study in Japanese Patients with T2DM
NCT00885118Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2009
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Change From Baseline in Urine Glucose Excretion at 28 days, Change From Baseline in Fasting Plasma Glucose at 28 days and 1 more. Started Apr 2009; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00885118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00885118.